BioCentury
ARTICLE | Clinical News

MitoQ: Completed Phase II enrollment

December 4, 2006 8:00 AM UTC

Antipodean completed enrollment of 128 patients in a double-blind, placebo-controlled, New Zealand and Australian Phase II trial. The trial is evaluating 40 and 80 mg doses of once-daily oral MitoQ. ...